Cost-Effectiveness of Strategies for Treatment Timing for Perinatally Acquired Hepatitis C Virus

New evidence shows treating HCV at 3 years old is projected to lead to improved clinical outcomes.

By Bonnie Tse May 2, 2024
In this modeling study, delaying treatment is projected to increase the burden of liver complications from hepatitis C virus.

Megan Rose Curtis, MD, MS

Key Findings

Treating children with perinatally-acquired HCV, as early as the age of 3, could increase life expectancy and decrease healthcare expenditures.